Long acting injectable HIV treatments provide an alternative to taking daily oral medication for certain people living with HIV. These treatments use antiretroviral medicines administered through injections at scheduled intervals, helping maintain control of the virus. Depending on the medication, injections may be given monthly or every two months after an initial treatment period.
HIV treatment has advanced significantly through the development of antiretroviral therapies that suppress viral replication and help protect immune function. Traditionally, many treatment plans have involved taking oral medication every day. Long acting injectable treatments offer another approach for eligible individuals by delivering medicines over extended periods. These options can reduce the need for daily pills, although they still require regular healthcare appointments, appropriate monitoring, and adherence to the prescribed injection schedule. They are not suitable for everyone, and treatment decisions should be made with an HIV specialist.
Long acting injectable HIV treatment uses medicines that remain active in the body for an extended period. The injections contain antiretroviral drugs that target different stages of the HIV life cycle. By preventing the virus from multiplying, these medicines help maintain viral suppression when used according to the prescribed schedule.
One established option is the combination of cabotegravir and rilpivirine, marketed as Cabenuva in the United States. Cabotegravir is an integrase strand transfer inhibitor, while rilpivirine is a non-nucleoside reverse transcriptase inhibitor. Together, they help prevent HIV from replicating.
Important characteristics of this treatment include:
Administration schedule: Injections are generally given once a month or every two months, depending on the prescribed regimen.
Initial treatment: Some patients may receive oral lead-in medication before injections, while others may begin injections directly when clinically appropriate.
Treatment eligibility: The regimen is intended for eligible people whose HIV is already suppressed on treatment, subject to the applicable prescribing criteria.
Clinical monitoring: Healthcare professionals assess viral load, treatment history, potential drug interactions, and other relevant factors.
Missed appointments: Delayed injections can increase the risk of viral rebound and drug resistance, so planned appointments and alternative medication arrangements are important.
Long acting injectable treatment is not the same as HIV prevention medication. Injectable cabotegravir alone is also used for pre-exposure prophylaxis, known as PrEP, in people who do not have HIV. The appropriate medicine and dosing schedule depend on whether the purpose is treatment or prevention.
For eligible individuals, injectable treatment may make HIV management more convenient by replacing daily oral dosing with scheduled clinic visits. Some people appreciate having fewer medication-related tasks at home, while others may prefer the flexibility of oral treatment. The choice depends on individual preferences, medical circumstances, and access to consistent healthcare.
Several considerations can help patients understand this treatment approach:
Potential benefits: Fewer daily pills, predictable treatment appointments, and an alternative for people who prefer injections.
Possible side effects: Injection-site pain, swelling, redness, headache, fever, fatigue, or muscle pain may occur. Most injection-site reactions are temporary, but persistent or severe symptoms require medical attention.
Drug resistance: Inadequate drug levels, missed injections, or treatment failure can contribute to resistance, potentially limiting future treatment options.
Long lasting drug activity: The medicines can remain in the body for months after the last injection. If treatment is discontinued, a healthcare professional must arrange an appropriate alternative antiretroviral regimen.
Individual suitability: Certain drug interactions, previous treatment failure, resistance to the medicines, and specific medical circumstances may affect eligibility.
Patients should continue attending scheduled appointments and follow their clinician's instructions. Injectable therapy does not cure HIV, and it does not eliminate the need for viral load monitoring or other routine healthcare.
Long acting injectable HIV treatment represents an important development in HIV care, offering an alternative to daily oral medication for selected patients. Understanding how the medicines work, their eligibility requirements, potential side effects, and follow-up needs helps individuals make informed decisions with their healthcare team. Treatment selection should always be based on clinical assessment and current prescribing guidance.